학술논문
Adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies—Report from the Allergen Immunotherapy Adverse Events Registry (ADER), a European Academy of Allergy and Clinical Immunology taskforce
Document Type
article
Author
Julijana Asllani; Dimitrios Mitsias; George Konstantinou; Eris Mesonjesi; Fatmira Xhixha; Esmeralda Shehu; George Christoff; Katia Noleva; Michael Makris; Xenofon Aggelidis; Mirjana Turkalj; Erceg Damir; Ioana Agache; Vesna Tomic‐Spiric; Rajica Stosovic; Zeynep Misirligil; Mitja Kosnik; Todor A. Popov; Moises Calderon; Nikolaos G. Papadopoulos; ADER study group
Source
Clinical and Translational Allergy, Vol 13, Iss 6, Pp n/a-n/a (2023)
Subject
Language
English
ISSN
2045-7022
Abstract
Abstract Background Although it has been shown that allergen immunotherapy (AIT) is well‐tolerated in children, systematic and prospective surveillance of AIT safety in real life settings is needed. Methods The multinational Allergen Immunotherapy Adverse Events Registry (ADER) was designed to address AIT safety in real life clinical practice. Data on children ≤18 years old with respiratory allergies undergoing AIT were retrieved. Patient‐ and AIT‐related features were collected and analyzed. The characteristics of adverse events (AE) and risk factors were evaluated. Results A total of 851 patients, 11.3 ± 3.4 years old, with rhinitis only (47.6%); asthma and rhinitis (44.5%); asthma (7.9%), receiving 998 AIT courses were analyzed. Sublingual immunotherapy (SLIT) accounted for 51% of the courses. In 84.5% of patients only one AIT treatment was prescribed. Pollen was the most frequent sensitizer (57.1%), followed by mites (53.4%), molds (18.2%) and epithelia (16.7%). Local and systemic AEs were reported in 85 patients (9.9%). Most AEs (83.1%) were mild and occurred in